Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers
- PMID: 16649872
- DOI: 10.1037/0022-006X.74.2.276
Analyzing milestones in smoking cessation: illustration in a nicotine patch trial in adult smokers
Abstract
Tests of addiction treatments seldom reveal where treatment exercises its effect (i.e., promoting initial abstinence, preventing lapses, and/or impeding progression from lapse to relapse). The authors illustrate analyses distinguishing effects on these milestones in a randomized trial of high-dose nicotine patch (35 mg; n = 188) versus placebo (n = 136) in adult smokers, who used electronic diaries to monitor smoking in real time during 5 weeks of treatment. High-dose patch promoted initial abstinence (hazard ratio [HR] = 1.3) and decreased the risk of lapsing among those who achieved abstinence (HR = 1.6). The biggest effect of treatment was to prevent progression to relapse among those who had lapsed (HR = 7.1). Analysis of effects by milestones may enhance understanding of cessation treatments and their mechanisms of action.
Copyright 2006 APA
Similar articles
-
Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers.Clin Ther. 2009 Sep;31(9):1957-65. doi: 10.1016/j.clinthera.2009.08.029. Clin Ther. 2009. PMID: 19843485
-
Effect of high-dose nicotine patch on the characteristics of lapse episodes.Health Psychol. 2010 Jul;29(4):358-66. doi: 10.1037/a0019367. Health Psychol. 2010. PMID: 20658822 Clinical Trial.
-
Smoker characteristics and smoking-cessation milestones.Am J Prev Med. 2011 Mar;40(3):286-94. doi: 10.1016/j.amepre.2010.11.016. Am J Prev Med. 2011. PMID: 21335259 Free PMC article. Clinical Trial.
-
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.Cochrane Database Syst Rev. 2019 Apr 18;4(4):CD013308. doi: 10.1002/14651858.CD013308. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2023 Jun 19;6:CD013308. doi: 10.1002/14651858.CD013308.pub2. PMID: 30997928 Free PMC article. Updated.
-
Effects of the nicotine patch on performance during the first week of smoking cessation.Nicotine Tob Res. 2003 Apr;5(2):169-80. doi: 10.1080/1462220031000074873. Nicotine Tob Res. 2003. PMID: 12745489 Review.
Cited by
-
An ecological momentary assessment analysis of prequit markers for smoking-cessation failure.Exp Clin Psychopharmacol. 2012 Dec;20(6):479-88. doi: 10.1037/a0029725. Epub 2012 Aug 27. Exp Clin Psychopharmacol. 2012. PMID: 22924702 Free PMC article.
-
Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure.Psychopharmacology (Berl). 2006 Nov;189(1):1-16. doi: 10.1007/s00213-006-0529-6. Epub 2006 Sep 22. Psychopharmacology (Berl). 2006. PMID: 17019567 Free PMC article. Review.
-
Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Addiction. 2013 Dec;108(12):2202-11. doi: 10.1111/add.12325. Epub 2013 Sep 18. Addiction. 2013. PMID: 23941313 Free PMC article. Clinical Trial.
-
Markov model of smoking cessation.Proc Natl Acad Sci U S A. 2011 Sep 13;108 Suppl 3(Suppl 3):15549-56. doi: 10.1073/pnas.1011277108. Epub 2011 Apr 20. Proc Natl Acad Sci U S A. 2011. PMID: 21508324 Free PMC article.
-
Rates and predictors of renewed quitting after relapse during a one-year follow-up among primary care patients.Ann Behav Med. 2015 Feb;49(1):128-40. doi: 10.1007/s12160-014-9627-6. Ann Behav Med. 2015. PMID: 24796541 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical